Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

A New Tool to Tackle Neurological Disorders

By Drug Discovery Trends Editor | June 4, 2015

In a world first, neuroscientists at Flinders University have identified a series of chemical tools that can either increase or inhibit the release of neurotransmitters by neurons, the cells of the brain.

While not yet applied to a specific disease, the discovery has a wide range of potential pharmaceutical applications in neurological conditions ranging from schizophrenia to depression.

A team led by Associate Professor Damien Keating, a National Health and Medical Research Council (NHMRC) Research Fellow in the Department of Human Physiology and the Centre for Neuroscience at Flinders, has published a paper on the action of a protein called dynamin in the latest issue of the prestigious journal Molecular Psychiatry.

Vesicles – small spherical bodies within cells – contain active chemicals that can include neurotransmitters or hormones. Associate Professor Keating’s research is concerned with the process which sees vesicles move to the surface of a cell before opening a pore that allows the release of these active chemicals. The opening is then reversed and the vesicle moves back down into the cell to be reused.

Associate Professor Keating’s current research focuses on a protein named dynamin, already known to drive the process of resealing and recycling these vesicles. The breakthrough discovery has established that dynamin is also involved earlier in the process, and is a master regulator of the amount of neurotransmitter released from each vesicle.

Associate Professor Keating said the opening and closing of fusion pores – the vesicle’s temporary door through the cell wall – is dynamic, with differences in the size and duration of the opening controlling the amount of active chemical that is released.

Variations in levels of dynamin directly affect that process, and it is a process that underpins all our neuronal communication and hormone release, Associate Professor Keating said.

“If we activate dynamin, more is released by the vesicle; if we inhibit it, less is released,” he said. “This is fundamental new knowledge about a process that is essential to life in all organisms.”

Associate Professor Keating is collaborating with medicinal chemists and cell biologists in Sydney and Newcastle to further develop and refine these dynamin-based drugs.

“This research is novel in terms of identifying what this protein does – it plays a major new role that we did not know about – and it is novel in terms of the use of these drugs and their potential application,” he said.

“There is a lot work to be done to see how these drugs can be applied, but any neurological or metabolic disorder where neuronal or hormone signalling is a factor is a possible target, and any drug that can affect how much neurotransmitter or hormone is available has potential for usage in treatment,” he said.

Source: Flinders University


Filed Under: Genomics/Proteomics

 

Related Articles Read More >

Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classification
Spatial biology: Transforming our understanding of cellular environments
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
DNA helix 3D illustration. Mutations under microscope. Decoding genome. Virtual modeling of chemical processes. Hi-tech in medicine
Genomics in 2025: How $500 whole genome sequencing could democratize genomic data
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE